Understanding how purinergic signals affect blood vessel health and clotting
Purinergic regulation of Innate Immunity to promote Venous Homeostasis
This study is looking at how a protein called CD39 helps control inflammation and blood clotting, which could lead to better ways to prevent serious conditions like deep vein thrombosis and pulmonary embolism.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10794961 on NIH RePORTER |
What this research studies
This research investigates the role of purinergic signaling in regulating innate immunity and maintaining venous homeostasis, particularly in the context of deep venous thrombosis (DVT) and pulmonary embolism. The study focuses on a protein called CD39, which helps to manage inflammation and coagulation by breaking down certain molecules that signal danger in the body. By using specialized mouse models, researchers aim to uncover how CD39 influences the interactions between blood cells and the formation of clots, which could lead to new therapeutic strategies for preventing these serious conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for deep venous thrombosis or pulmonary embolism, particularly those with underlying cardiovascular conditions.
Not a fit: Patients who do not have any risk factors for venous thromboembolism or those with unrelated health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent dangerous blood clots and improve vascular health.
How similar studies have performed: Previous research has shown promising results in understanding the role of purinergic signaling in inflammation and coagulation, suggesting that this approach could yield significant insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Pinsky, David J. — University of Michigan at Ann Arbor
- Study coordinator: Pinsky, David J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.